What Is Real-World Evidence And Why Do We Need It?

.

這是由Merck Fertility Team提供的 #ESHRE2020 會前會 #Meet_The_Expert_Series 中第一場線上會議，在目前COVID-19疫情緊張，無法出國開會的情境下，可以稍稍化解遺憾！

.

#題目：What Is Real-World Evidence And Why Do We Need It?

.

#講師：Prof. Alberto Revelli, S. Anna Hospital, University of Torino, Italy.

.

日期：2020/06/25 3:00PM - 3:45PM

.

#結論：

.

#ART的當前趨勢顯然指向更好的療效定義和治療方案的個性化。

The current trends in ART point clearly toward the better definition of efficacy and the personalization of treatment protocols.

.

#隨機對照試驗RCT仍然是證據的基本來源，#但是具有相當的局限性，#即使將其分組進行統合分析仍無法克服此項限制。

RCTs are still a fundamental source of evidence, but have relevant limitations, that are not overcome by grouping them into a meta-analysis.

.

#真實世界證據RWE來自常規臨床活動中獲得的大量觀察結果，#沒有任何類型的患者選擇或遵循令人信服的規則。

RWE comes from a huge number of observations obtained in the routine clinical activity, without any kind of patient selection or compelling rules to be followed in the procedures.

.

#數據的數量和質量對於確定RWE的價值很重要。

Quantity and quality of data (patients, cycles) are important to determine the value of RWE.

.

#RCT和RWE可以藉由臨床應用所提供的科學證據來相互補充。

RCTs and RWE may complement each other by providing scientific evidence that applies to clinical daily practice.

.

#例如：#RWE顯示IVF療程中對於高齡預後較差的患者通常會使用rFSH與rLH比例為2比1配置的處方。

As an example of its application, RWE shows how the r-hFSH:r-hLH 2:1 formulation is usually prescribed to older, poor prognosis patients undergoing IVF.

.

#儘管選擇了這種不利條件，#但最終獲得的活產率與僅接受rFSH的預後較好的患者相當，#在大於35歲的患者活產OR為1點53。

Despite this unfavorable selection, it finally obtains a delivery rate comparable to that of better prognosis patients receiving r-hFSH alone, and in patients >35 is associated with an OR for delivery of 1.53.

.

DISCOVER NEW INSIGHTS ON THE HOTTEST TOPICS IN THE FIELD OF FERTILITY DURING OUR PRE-ESHRE MEET THE EXPERT SESSIONS

.